Our Mission

To revolutionize the diagnostic, prognostic, and predictive treatment of disease by enabling next generation technologies for non-destructively processing and digitally analyzing tissue in 3D.

Karl Deisseroth, MD, PhD

Founder & Scientific Advisor

Karl Deisseroth is the D.H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences at Stanford University, and Investigator of the Howard Hughes Medical Institute. He received his undergraduate degree from Harvard, his PhD from Stanford, and his MD from Stanford; he also completed postdoctoral training, medical internship, and adult psychiatry residency at Stanford, and he is board-certified by the American Board of Psychiatry and Neurology. He continues as a practicing psychiatrist at Stanford with specialization in affective disorders and autism-spectrum disease, employing medications along with neural stimulation.
Over a period of twelve years, his laboratory created and developed optogenetics, hydrogel-tissue chemistry (beginning with CLARITY), and a broad range of supportive and enabling methods. He also has employed his technologies to discover the neural cell types and connections that cause adaptive and maladaptive behaviors, and has disseminated the technologies to thousands of laboratories around the world.
For his discoveries, Deisseroth has received the NIH Director's Pioneer Award (2005), the Zuelch Prize (2012), the PerlPrize (2012), the BRAIN prize (2013), the Pasarow Prize (2013), the Breakthrough Prize (2015) the BBVA Award (2016), the Massry Prize (2016) and the Harvey Prize from the Technion/Israel (2017), and among other honors, was the sole recipient for optogenetics of the 2010 Koetser Prize, the 2010 Nakasone Prize, the 2011 Alden Spencer Prize, the 2013 Richard Lounsbery Prize, the 2014 Dickson Prize in Science, the 2015 Keio Prize, the 2015 Lurie Prize, the 2015 Albany Prize, the 2015 Dickson Prize in Medicine, the 2017 Redelsheimer Prize, the 2017 Fresenius Prize, the 2017 NOMIS Distinguished Scientist Award, the 2018 Eisenberg Prize, and the 2018 Kyoto Prize. He was selected a Howard Hughes Medical Institute Investigator in 2013, and was elected to the US National Academy of Medicine in 2010 and to the US National Academy of Sciences in 2012.

Laurie Goodman, PhD

CEO and Board Manager

Dr. Goodman brings more than 25 years experience with innovative technology development, clinical cancer diagnostics, and translational cancer research within the biotechnology industry. She has held broad senior level roles encompassing research and development as well as clinical and medical affairs. Most recently she held the position of Senior Director of Scientific and Medical Affairs for Biodesix, an innovator of blood-based cancer diagnostics.

She was instrumental in building and leading the company's first scientific and medical affairs team as well initiating/leading key academic collaborations in the areas of lung and breast cancer. Other senior level roles included directing the analytic team involved in the CLIA validation and commercialization of Monogram Biosciences first oncology diagnostic product, HERmark®. Following a postdoctoral fellowship at Genentech, she began her career at Lynx Therapeutics (currently Illumina) where she initiated and developed a breast cancer scientific program to validate the company's next generation sequencing platform.

Dr. Goodman is an author on several key publications and patents related to analytic and clinical cancer biomarkers. She holds a BS degree in Biology with a minor in Chemistry from Arizona State University and a PhD in Cell and Molecular Biology from University of California Berkeley.

Scientific Advisors

Sunil Badve, MD

Joshua Edwards Professor of Pathology and Laboratory Department of Pathology and Laboratory Medicine IU School of Medicine

Adriano Aguzzi, MD, PhD

Chairman, Department of Pathology, University Hospital of Zurich

NOMIS Distinguished Scientist Awardee 2019

David Eberhard MD, PhD

Senior Medical Director, Oncology at Illumina

Study Shows Promise for Revolutionizing Spatial Tumor Analysis.


Non-destructive tissue processing and digital spatial image analysis in 3D to facilitate your pre-clinical and clinical research studies

A way to illuminate your tissue microenvironment in a 3D volume

Automating this process and integrating it into your normal tissue processing work flow

ClearLight Biotechnologies’ automated instrumentation platform study is featured as the 4th news story in Clinical Lab Products’ Prime email newsletter and on Clinical Lab Products’ magazine.

ClearLight Biotechnologies and Researchers at the Indiana University’s Melvin and Bren Simon Cancer Center
Announce publication in Scientific Reports-Nature

ClearLight Biotechnologies (formerly ClearLight Diagnostics, LLC) was founded in 2014 by Karl Deisseroth MD, PhD, the inventor of CLARITY, Optogenetics, and STARmap technologies. It is an early stage company focused on developing automated instrumentation and associated reagents to simplify and expedite non-destructive 3D tissue analysis to facilitate preclinical and clinical research applications. The platform will enable an end-to-end solution for 3D analysis of preclinical and clinical models of disease.

Sharla White, PhD presented poster #4690 at AACR Annual Meeting 2019, Atlanta.

Nature posted a video to YouTube describing the CLARITY 3D tissue imaging technology.

View on YouTube

4 Major Platform Components

Multi-sample 3D Tissue Processor
Multi-color/ sample 3D Imaging
Custom 3D Image Analysis Software
Development of Key Biomarker Panels


Could be applied to any application that relies
on 2D thin section FFPE analysis


Near Term

Research Use Only (RUO) Service Model
and Limited Beta instruments in field

Preclinical/clinical drug development, exploratory technology inclusion in clinical trials


RUO instrument in field, Companion Diagnostics, LDT (ClearLight Biotechnologies has exclusive rights to diagnostic, prognostic, predictive applications)

Extensive External Network Support

Stay informed

Stay up to date with ClearLight’s advances in 3D Tissue Spatial Analysis and CLARITY. We’ll never share your email address or information.